ZAGO am Helios Klinikum Krefeld
Welcome,         Profile    Billing    Logout  
 8 Trials 
17 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Sehouli, Jalid
COMPASS, NCT03164980: Comparison of QoL Between Trabectedin/PLD and Standard Platinum-based Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer

Completed
4
89
Europe
Trabectidin (Yondelis)
North Eastern German Society of Gynaecological Oncology, Frankfurter Institut für Klinische Krebsforschung IKF GmbH, PharmaMar
Quality of Life, Ovarian Cancer, Recurrent Ovarian Carcinoma
08/23
08/23
MAMOC, NCT04227522: Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients

Completed
3
42
Europe
Rucaparib, Placebos
North Eastern German Society of Gynaecological Oncology, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Clovis Oncology, Inc.
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Clear Cell Carcinoma
12/23
07/24
ENGOT-EN20, NCT05611931: Selinexor in Maintenance Therapy After Systemic Therapy for Participants with P53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Calendar Jul 2024 - Dec 2024: Top-line data from XPORT-EC trial in participants with TP53 wild type endometrial cancer
Recruiting
3
220
Europe, Canada, US, RoW
Selinexor, KPT-330, Matching Placebo for selinexor
Karyopharm Therapeutics Inc, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Belgium and Luxembourg Gynaecological Oncology Group, North Eastern German Society of Gynaecological Oncology, Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies, Spanish Research Group in Ovarian Cancer, The Central and Eastern European Gynecologic Oncology Group, Israeli Society of Gynecologic Oncology, Australia New Zealand Gynaecological Oncology Group
Endometrial Cancer
01/25
01/28
NCT02203760 / 2012-003810-15: Pazopanib Vs. Pazopanib Plus Gemcitabine

Active, not recruiting
2
58
Europe
Pazopanib plus Gemcitabine, Votrient and Gemzar, Pazopanib, Votrient
North Eastern German Society of Gynaecological Oncology, Novartis Pharmaceuticals, medac GmbH
Leiomyosarcoma or Carcinosarcoma
12/24
12/24
MIROVA, NCT04274426: Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer

Active, not recruiting
2
136
Europe
Carboplatin, Pegylated liposomal doxorubicin (PLD), Gemcitabine, Paclitaxel, Mirvetuximab Soravtansine
AGO Research GmbH
Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma
12/25
12/26
PERCEPTION, NCT04575961: Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer

Recruiting
2
33
Europe
Pembrolizumab, Keytruda
North Eastern German Society of Gynaecological Oncology, Merck Sharp & Dohme LLC
Ovarian Cancer, Low Grade Serous Carcinoma, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
04/25
11/26
N-Plus, NCT05460000: A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy

Recruiting
2
640
Europe
3 cycles chemotherapy instead of 6 cycles chemotherapy, 6 cycles chemotherapy
North Eastern German Society of Gynaecological Oncology, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Clear Cell Carcinoma
05/27
05/32
WoO, NCT04644289: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC

Recruiting
2
60
Europe
olaparib, Lynparza, durvalumab, Imfinzi
AGO Research GmbH
Epithelial Ovarian Cancer
01/28
06/28
BENITA, NCT06250686: Exercise and Nutrition Intervention in Ovarian Cancer

Recruiting
N/A
185
Europe
combined exercise and nutrition intervention
Universitätsklinikum Hamburg-Eppendorf, Charite University, Berlin, Germany, University Hospital Dresden, Kliniken Essen-Mitte, University Hospital Tuebingen, University Hospital Schleswig-Holstein, Technical University of Munich
Ovarian Cancer, Malnutrition, Muscle Wasting, Fatigue
07/25
12/25
TRacKING, NCT04921553: Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions

Recruiting
N/A
500
Europe, RoW
Data collection and quality of life questionnaire
Centre Leon Berard
Cancer, Cancer Metastatic, NTRK Gene Fusion Overexpression, NTRK Family Gene Mutation, ATIC-ALK Fusion Protein Expression, ALK Fusion Protein Expression, BCR-FGFR1 Fusion Protein Expression, ROS1 Gene Translocation, COL1A1-PDGFB Fusion Protein Expression, RET Gene Translocation, Gene Fusion, ROS Gene Translocation, BRAF Gene Rearrangement, FGFR2 Gene Translocation, FGFR3 Gene Translocation, NTRK1 Gene Translocation
06/25
06/25
NCT01763125: Establishment of a Tumor Bank for Blood Samples

Recruiting
N/A
10000
Europe
Blood collection
Medical University of Vienna
Ovarian Neoplasms, Breast Neoplasms, Colorectal Neoplasms, Neoplasms of the Female Genitalia, Lung Neoplasms, Endocrine Gland Neoplasms
12/26
12/26
Rogmans, Gunther
CAPTOR-BC, NCT05452213: Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients

Recruiting
4
1000
Europe
Ribociclib
Institut fuer Frauengesundheit, AGO Breast Study Group e.V., Novartis Pharmaceuticals
Breast Cancer, Breast Neoplasms, Breast Neoplasm Female, Breast Cancer Female, HER2-negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Advanced Breast Cancer
10/24
10/26
ADAPTlate, NCT04565054 / 2019-001488-60: Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC

Recruiting
3
1260
Europe
Abemaciclib 50 MG; 150mg 1-0-1 per os, Verzenios
West German Study Group, Eli Lilly and Company, Genomic Health®, Inc.
Breast Cancer Female
08/26
03/28
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
MIROVA, NCT04274426: Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer

Active, not recruiting
2
136
Europe
Carboplatin, Pegylated liposomal doxorubicin (PLD), Gemcitabine, Paclitaxel, Mirvetuximab Soravtansine
AGO Research GmbH
Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma
12/25
12/26
PROOFS, NCT05792150: -Registry - Premenopausal Women With Breast Cancer Optimally Treated With OFS

Recruiting
N/A
1470
Europe
West German Study Group, Agendia
Female Breast Cancer
03/35
06/35
Uysal, Songül
NCT05213416: BETY-BIOPSYCHOSOCIAL QUESTIONNAIRE IN PARTİCİPANTS RECEIVING RADIOTHERAPY

Recruiting
N/A
150
RoW
Hacettepe University
Questionnaire, Radiotherapy
12/24
12/24

Download Options